Obinutuzumab-based Therapy Prolongs PFS in Untreated Follicular Lymphoma

Share this content:
Obinutuzumab-based induction and maintenance chemoimmunotherapy significantly improved progression-free survival.
Obinutuzumab-based induction and maintenance chemoimmunotherapy significantly improved progression-free survival.

SAN DIEGO Among patients with previously untreated follicular lymphoma, obinutuzumab-based induction and maintenance chemoimmunotherapy significantly improved progression-free survival compared with rituximab-based therapy, according to a study presented during the plenary session of the American Society of Hematology (ASH) 58th Annual Meeting and Exposition.1

"There is significant benefit with rituximab-based induction plus maintenance in patients with previously-untreated, advanced-stage, symptomatic follicular lymphoma," said principal investigator Robert E. Marcus, MBBS, FRCP, FRCPath, Kings College Hospital, London, United Kingdom. “Obinutuzumab, a glycol-engineered type 2 anti-CD20 monoclonal antibody, has been shown to prolong progression-free survival when combined with bendamustine in rituximab-refractory indolent non-Hodgkin lymphoma.”

For this cohort of the open-label, phase 3 GALLIUM study (ClinicalTrials.gov Identifier: NCT01332968), researchers enrolled 1202 patients with previously untreated, grade 1-3a, follicular lymphoma to compare the efficacy and safety of obinutuzumab-based and rituximab-based regimens.

Participants were randomly assigned 1:1 to rituximab or obinutuzumab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or CVP (cyclophosphamide, bortezomib, prednisone) chemotherapy. Patients with a complete or partial response at the end of induction received rituximab or obinutuzumab maintenance every 2 months for 2 years or until disease progression.

After a median follow-up of 34.5 months, results showed that obinutuzumab-based therapy reduced the risk of progression or death by 34% compared with rituximab-based therapy (hazard ratio, 0.66; 95% CI, 0.51-0.85; P = .0012), leading to an approximately 1.5 times longer median progression-free survival with obinutuzumab vs rituximab.

The 3-year progression-free survival rates per investigator assessment were 80.0% (95% CI, 75.9-83.6) with obinutuzumab-chemotherapy and 73.3% (95% CI, 68.8-77.2) with rituximab-chemotherapy.

“Obinutuzumab-chemotherapy plus maintenance is superior to rituximab-chemotherapy plus maintenance in untreated follicular lymphoma patients in this interim efficacy analysis,” said Dr Marcus. “The progression-free survival results are supported by other time-to-event endpoints.”

The study did not, however, demonstrate a significant difference in overall survival between the 2 treatment arms (hazard ratio, 0.75; 95% CI, 0.49-1.17; P = .21).

Obinutuzumab-based therapy was associated with a higher frequency of grade 3 to 5 and serious adverse events, including infusion-related reaction, cytopenias, and infections vs rituximab-based therapy.

RELATED: Chemo-free Induction Efficacious in Younger Patients With Mantle Cell Lymphoma

“Non-fatal adverse events were higher in the obinutuzumab arm,” Dr Marcus added. “Fatal adverse events were more common in patients on bendamustine in both arms.

“Obinutuzumab-based therapy significantly improves outcome compared with rituximab-based therapy and should now be considered as a first-line treatment for follicular lymphoma,” Dr Marcus concluded.

Reference

  1. Marcus RE, Davies AJ, Ando K, et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: Primary results of the randomized phase 3 GALLIUM study. Paper presented at: American Society of Hematology (ASH) 58th Annual Meeting and Exposition; December 3-6, 2016; San Diego, CA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs